Edition:
India

Abeona Therapeutics Inc (ABEO.OQ)

ABEO.OQ on NASDAQ Stock Exchange Capital Market

3.74USD
19 Jul 2019
Change (% chg)

$-0.10 (-2.60%)
Prev Close
$3.84
Open
$3.85
Day's High
$3.91
Day's Low
$3.73
Volume
104,366
Avg. Vol
145,560
52-wk High
$15.60
52-wk Low
$3.73

Latest Key Developments (Source: Significant Developments)

Abeona Therapeutics Announces FDA Clearance Of Investigational New Drug Application For ABO-202 Gene Therapy In Cln1 Disease
Tuesday, 21 May 2019 

May 21 (Reuters) - Abeona Therapeutics Inc ::ABEONA THERAPEUTICS ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR ABO-202 GENE THERAPY IN CLN1 DISEASE.ABEONA THERAPEUTICS - CO IS CLEARED TO BEGIN PHASE 1/2 CLINICAL TRIAL EVALUATING ITS NOVEL, ONE-TIME GENE THERAPY ABO-202 FOR TREATMENT OF CLN1 DISEASE.ABEONA THERAPEUTICS INC - "WE ARE VERY ENCOURAGED THAT ABO-202 WAS WELL-TOLERATED AND DEMONSTRATED SIGNIFICANT EFFICACY IN PRECLINICAL STUDIES.".  Full Article

Abeona Therapeutics Reports Q1 Loss Per Share $0.39
Saturday, 11 May 2019 

May 10 (Reuters) - Abeona Therapeutics Inc ::ABEONA THERAPEUTICS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS.Q1 LOSS PER SHARE $0.39.Q1 EARNINGS PER SHARE ESTIMATE $-0.32 -- REFINITIV IBES DATA.CMC WORK COMPLETED IN ADVANCE OF EB-101 PHASE 3 VITAL™ TRIAL EXPECTED TO BEGIN MID-2019.ABEONA THERAPEUTICS - CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF MARCH 31, 2019 WERE $68.3 MILLION, COMPARED TO $85.0 MILLION AS OF DECEMBER 31.  Full Article

Abeona Therapeutics Q1 Loss Per Share $0.39
Saturday, 11 May 2019 

May 10 (Reuters) - Abeona Therapeutics Inc ::ABEONA THERAPEUTICS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS.Q1 LOSS PER SHARE $0.39.Q1 EARNINGS PER SHARE ESTIMATE $-0.32 -- REFINITIV IBES DATA.  Full Article

Abeona Therapeutics Receives FDA Fast Track Designation For ABO-101 For Treatment Of Sanfilippo Syndrome Type B (MPS IIIB)
Thursday, 4 Apr 2019 

April 4 (Reuters) - Abeona Therapeutics Inc ::ABEONA THERAPEUTICS RECEIVES FDA FAST TRACK DESIGNATION FOR ABO-101 FOR TREATMENT OF SANFILIPPO SYNDROME TYPE B (MPS IIIB).ABEONA THERAPEUTICS INC - ABEONA IS ENROLLING ELIGIBLE PATIENTS WITH MPS IIIB AT SITES IN U.S. AND SPAIN.  Full Article

Abeona Therapeutics Says João Siffert Will Not Serve On Board During His Tenure As Interim CEO
Friday, 30 Nov 2018 

Nov 30 (Reuters) - Abeona Therapeutics Inc ::ABEONA THERAPEUTICS INC - JOÃO SIFFERT WILL NOT SERVE ON BOARD OF DIRECTORS DURING HIS TENURE AS INTERIM CHIEF EXECUTIVE OFFICER - SEC FILING.ABEONA THERAPEUTICS - ON NOV 29, FRANK CARSTEN THIEL, CO ENTERED SEPARATION AGREEMENT.ABEONA THERAPEUTICS - SEPARATION AGREEMENT PROVIDING FRANK CARSTEN THIEL WILL NOT OTHERWISE BE ELIGIBLE FOR ANY ANNUAL BONUS OR SEVERANCE AMOUNT.  Full Article

Abeona Therapeutics Announces CEO Transition
Tuesday, 27 Nov 2018 

Nov 26 (Reuters) - Abeona Therapeutics Inc ::ABEONA THERAPEUTICS ANNOUNCES CEO TRANSITION.ABEONA THERAPEUTICS INC - ANNOUNCED IMMEDIATE TERMINATION OF ITS CHIEF EXECUTIVE OFFICER, CARSTEN THIEL.ABEONA THERAPEUTICS INC - HAS APPOINTED JOÃO SIFFERT, AS INTERIM CHIEF EXECUTIVE OFFICER.ABEONA THERAPEUTICS INC - TERMINATION OF CEO "DUE TO PERSONAL MISCONDUCT THAT VIOLATED COMPANY'S CODE OF BUSINESS CONDUCT AND ETHICS".ABEONA THERAPEUTICS - THIEL'S TERMINATION FOLLOWS INVESTIGATION BY BOARD, EXTERNAL COUNSEL INTO ALLEGATIONS OF MISCONDUCT TOWARDS COLLEAGUES.ABEONA THERAPEUTICS INC - BOARD HAS FORMED A SEARCH COMMITTEE TO IDENTIFY A PERMANENT SUCCESSOR, WITH ASSISTANCE OF A EXECUTIVE SEARCH FIRM.  Full Article

Abeona Therapeutics Q3 Loss Per Share $0.34
Saturday, 10 Nov 2018 

Nov 9 (Reuters) - Abeona Therapeutics Inc ::ABEONA THERAPEUTICS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS.Q3 LOSS PER SHARE $0.34.Q3 REVENUE $1.7 MILLION VERSUS $219,000.Q3 REVENUE VIEW $393,000 -- THOMSON REUTERS I/B/E/S.Q3 EARNINGS PER SHARE VIEW $-0.26 -- THOMSON REUTERS I/B/E/S.  Full Article

Abeona Therapeutics Q3 Loss Per Share $0.34
Saturday, 10 Nov 2018 

Nov 9 (Reuters) - Abeona Therapeutics Inc ::ABEONA THERAPEUTICS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS.Q3 LOSS PER SHARE $0.34.Q3 REVENUE $1.7 MILLION VERSUS $219,000.Q3 REVENUE VIEW $393,000 -- THOMSON REUTERS I/B/E/S.Q3 EARNINGS PER SHARE VIEW $-0.26 -- THOMSON REUTERS I/B/E/S.  Full Article

Abeona Therapeutics May Offer And Sell Common Shares Of Up To $150 Mln Through Jefferies
Saturday, 18 Aug 2018 

Aug 17 (Reuters) - Abeona Therapeutics Inc ::ABEONA THERAPEUTICS - MAY OFFER AND SELL COMMON SHARES OF UP TO $150 MILLION THROUGH JEFFERIES LLC.  Full Article

Abeona Therapeutics Q2 Loss Per Share $0.25
Friday, 10 Aug 2018 

Abeona Therapeutics Inc ::ABEONA THERAPEUTICS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS.Q2 LOSS PER SHARE $0.25.Q2 REVENUE $819,000 VERSUS $217,000.Q2 REVENUE VIEW $1.1 MILLION -- THOMSON REUTERS I/B/E/S.Q2 EARNINGS PER SHARE VIEW $-0.19 -- THOMSON REUTERS I/B/E/S.CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF JUNE 30, 2018 WERE $120 MILLION.  Full Article